1352303-16-2Relevant academic research and scientific papers
Sphingolipid analogues inhibit development of malaria parasites
Meyer, Esmeralda V. S.,Holt, Jason J.,Girard, Kathryn R.,Ballie, Mark T.,Bushnev, Anatoliy S.,Lapp, Stacey,Menaldino, David S.,Arrendale, Richard F.,Reddy, G. Prabhakar,Evers, Taylor J.,Howard, Randy B.,Culver, Deborah G.,Liotta, Dennis C.,Galinski, Mary R.,Natchus, Michael G.
, p. 43 - 47 (2012)
Plasmodium-infected erythrocytes have been shown to employ sphingolipids from both endogenous metabolism as well as existing host pools. Therapeutic agents that limit these supplies have thus emerged as intriguing, mechanistically distinct putative targets for the treatment of malaria infections. In an initial screen of our library of sphingolipid pathway modulators for efficacy against two strains of the predominant human malaria species Plasmodium falciparum and Plasmodium knowlesi, a series of orally available, 1-deoxysphingoid bases were found to possess promising in vitro antimalarial activity. To better understand the structural requirements that are necessary for this observed activity, a second series of modified analogues were prepared and evaluated. Initial pharmacokinetic assessments of key analogues were investigated to evaluate plasma and red blood cell concentrations in vivo.
Sphingosine Analogs, Compositions, and Methods Related Thereto
-
, (2014/10/29)
The disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing disease. In certain embodiments, the disclosure relates to methods of treating an infection or cancer comprising administering a pharmaceutical composition disclosed herein to a subject in need thereof. In a typical embodiment, one administers a pharmaceutical composition comprising sphingosine or a sphingosine analog to a subject at risk for, exhibiting symptoms of or diagnosed with a malaria infection.
